Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1939]

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Novel biomarkers in myeloma: CTCs and cfDNA

Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain

Novel biomarkers in myeloma: CTCs and cfDNA ( Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

WCI's role in the prevention of tobacco related cancer among Beedi rolling...

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

More from ecancer